Basit öğe kaydını göster

dc.contributor.authorHeukelom, Jolien
dc.contributor.authorKantor, Michael E.
dc.contributor.authorMohamed, Abdallah S. R.
dc.contributor.authorElhalawani, Hesham
dc.contributor.authorKoçak, Esengül
dc.contributor.authorLin, Timothy A.
dc.contributor.authorWilliamson, Ryan
dc.contributor.authorRasch, Coen
dc.contributor.authorFuller, Clifton David
dc.contributor.authorSonke, Jan Jakob
dc.date.accessioned2021-01-18T08:33:55Z
dc.date.available2021-01-18T08:33:55Z
dc.date.issued2018en_US
dc.identifier.citationHeukelom, J., Kantor, M. E., Mohamed, A. S. R., Elhalawani, H., Koçak, E., Lin, T. A. ... Sonke, J. J. (2018). The difference between planned and delivered dose for head and neck cancer, and the consequences for normal tissue toxicity probability. 60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) içinde (E224-E225. ss.). San Antonio, TX, October 21-24, 2018. https://dx.doi.org/10.1016/j.ijrobp.2018.07.770en_US
dc.identifier.issn0360-3016
dc.identifier.issn1879-355X
dc.identifier.urihttps://dx.doi.org/10.1016/j.ijrobp.2018.07.770
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6272
dc.description.abstractPurpose/Objective(s): Anatomical changes during radiation for head andneck cancer (HNC) induce differences between the planned and delivereddose. To account for this, an adapted treatment plan can be designed. Thedecision to do this is based on expert opinion after examination of inroomimages. The aims of this study were to 1. quantify the difference betweenplanned and delivered dose in HNC patients. 2. assess the consequentialdifference in normal tissue complication probability (DNTCP). 3. Assessthe positive predictive value (PPV) for the allocation of adaptive radiotherapy (ART) of clinical judgement vs. NTCP based on dose differencesat fraction 10 (F10) and 15 (F15).Materials/Methods: Daily CT scans in treatment position for 56 patientswere retrospectively analyzed. Delivered dose was calculated based on theanatomy of the day and subsequently mapped back to the planning CT toallow dose accumulation. The difference between planned and delivereddose was analyzed for CTVs and 9 organs at risk (OAR). DNTCP wascalculated for xerostomia, dysphagia, parotid gland dysfunction and tubefeeding dependency at 6 months post treatment (Tube6m) using previouslypublished NTCP models. ART was deemed necessary if DNTCP was>5%. To predict DNTCP at the end of treatment using the dose differenceat F10 or F15, the dose on that day was extrapolated to the full treatmentlength prior to the NTCP calculation. The PPV was calculated for identification of ART-patients by clinical judgement, DNTCP at F10 and F15.en_US
dc.description.sponsorshipElekta AB ; American Society for Radiation Oncology (ASTRO)en_US
dc.language.isoengen_US
dc.publisherElsevier Science Incen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectNeck Canceren_US
dc.subjectConsequencesen_US
dc.subjectNormal Tissueen_US
dc.subjectToxicity Probabilityen_US
dc.titleThe difference between planned and delivered dose for head and neck cancer, and the consequences for normal tissue toxicity probabilityen_US
dc.typeconferenceObjecten_US
dc.relation.ispartof60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)en_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.identifier.volume102en_US
dc.identifier.issue3en_US
dc.identifier.startpageE224en_US
dc.identifier.endpageE225en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.ijrobp.2018.07.770en_US
dc.identifier.wosqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster